Akums Drugs and Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical industry, is headquartered in Haridwar, Uttarakhand. Founded in 2004, the company has rapidly established itself as a leading manufacturer of a diverse range of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. With a strong focus on quality and innovation, Akums serves both domestic and international markets, catering to various therapeutic segments. The company is renowned for its state-of-the-art manufacturing facilities, which adhere to stringent regulatory standards, ensuring the delivery of high-quality medicines. Akums has achieved significant milestones, including numerous certifications and partnerships, solidifying its position as a trusted name in healthcare. Its commitment to excellence and customer satisfaction continues to drive its growth and reputation in the competitive pharmaceutical landscape.
How does Akums Drugs and Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Akums Drugs and Pharmaceuticals Limited's score of 11 is lower than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Akums Drugs and Pharmaceuticals Limited reported total carbon emissions of 20,000,000 kg CO2e, comprising 10,000,000 kg CO2e from Scope 1 and 10,000,000 kg CO2e from Scope 2. The company has not disclosed any Scope 3 emissions data. For 2024, emissions data is not yet available, but the company reported a CO2 emissions intensity of approximately 4,470 kg CO2e per tonne of Active Pharmaceutical Ingredient (API) produced. Despite the significant emissions reported, Akums has not established specific reduction targets or initiatives, nor have they committed to any climate pledges or SBTi targets. The emissions intensity metrics indicate a focus on improving efficiency in relation to revenue and production, with emissions intensity per INR million of revenue reported at about 0.0000001 kg CO2e. Overall, while Akums Drugs and Pharmaceuticals Limited has made strides in measuring their emissions, the absence of reduction commitments highlights an area for potential improvement in their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 10,000,000 |
| Scope 2 | 10,000,000 |
| Scope 3 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akums Drugs and Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
